ES 
EN /
/
The FDA is currently reviewing a potential treatment for focal segmental glomerulosclerosis (FSGS). Sign our letter to the FDA to ensure that the lived experiences of patients and caregivers are part of this decision. Your journey with FSGS matters. Your voice matters. And right now, it matters more than ever that you are heard. Sign NephCure's letter to the FDA by 2/18.
Sign now
NephCure es una organización benéfica sin fines de lucro (501c3) registrada y exenta de impuestos. EIN # 38-3569922.
© Copyright 2024 NephCure, Inc. Todos los derechos reservados en todo el mundo. NephCure y el logotipo son marcas comerciales registradas a nivel federal de NephCure, Inc.
